A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006898/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in
patients with non-metastatic prostate cancer
提供机构：
Vivli
创建时间：
2021-04-16
